CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：新型第三代抗 CD19/CD22 CAR-T 细胞联合 auto-HSCT 治疗复发伯基特淋巴瘤
英文原题：Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.
查看英文原题
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究探讨一种治疗复发/难治性伯基特淋巴瘤（BL）的新策略，即将自体造血干细胞移植（ASCT）与串联抗CD19/CD22嵌合抗原受体（CAR）T细胞疗法结合。一名20岁亚洲男性难治性BL患者对多种化学免疫治疗方案均无应答，接受清髓性ASCT，3天后输注新型第三代CAR-T 细胞。该细胞经工程化改造，含有CD28和CD3信号结构域以及TLR2共刺激结构域。随访至第306天时患者持续完全缓解，且未发生严重并发症。该病例提示，清髓性ASCT联合串联抗CD19/CD22 CAR-T 细胞疗法可能有效治疗复发/难治性BL，值得进一步临床验证。
展开英文摘要原文
This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3 signaling domains, along with a TLR2 costimulatory domain.
This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.
论文信息
- 作者
- Luo X、Chen A、Qin L、Weinkove R、Zhao R、Ye T、Chen S、Tang J
- 单位
- The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39717765 · DOI 10.3389/fimmu.2024.1497736
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →